Summary by Futu AI
Aclarion, Inc., a Delaware-based healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on November 1, 2024. The registration pertains to the issuance of up to 27,515,153 shares of common stock, which includes shares issuable upon conversion of Series C Convertible Preferred Stock and upon the exercise of warrants. The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. Aclarion has not specified the timing of the sale of these securities, indicating that the sale may occur from time to time after the effective date of the registration statement. The company will not receive any proceeds from the sale of shares by the selling stockholders but may receive proceeds from the exercise of the warrants. The registration statement also includes provisions for indemnification of directors and officers, details on the company's capital stock, and the legal and expert opinions related to the offering.
